ABT — Abbott Laboratories Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapHigh Flyer

Annual income statement for Abbott Laboratories, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	34,608	43,075	43,653	40,109	41,950
Cost of Revenue
Gross Profit	19,641	24,585	24,570	22,190	23,306
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	29,136	34,650	35,336	33,670	35,307
Operating Profit	5,472	8,425	8,317	6,439	6,643
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	4,968	8,211	8,306	6,664	7,013
Provision for Income Taxes
Net Income After Taxes	4,497	7,071	6,933	5,723	13,402
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	4,495	7,071	6,933	5,723	13,402
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	4,495	7,071	6,933	5,723	13,402
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.5	4.03	4.12	3.43	7.81
Dividends per Share